Literature DB >> 29766265

Surgery for subependymal giant cell astrocytomas in children with tuberous sclerosis complex.

Martine Fohlen1, Sarah Ferrand-Sorbets2, Olivier Delalande2, Georg Dorfmüller2.   

Abstract

OBJECTIVE: Subependymal giant cell astrocytomas (SEGAs) are low-grade intraventricular glial tumors that develop in 10-15% of patients with tuberous sclerosis complex; they often cause hydrocephalus and are potentially accessible to a surgical treatment. Our aim is to evaluate morbidity and results after surgery in symptomatic and asymptomatic patients.
METHOD: We present a retrospective series of 18 pediatric patients operated on for SEGA between 2006 and 2016 at our institution. We reviewed surgical indications, preoperative clinical and radiologic data, surgical management, and clinical and radiological follow-up.
RESULTS: Mean age at surgery was 10.7 years. The surgical decision was based on clinical signs of raised intracranial pressure due to hydrocephalus in 8 and on radiological findings without any clinical signs in the other 10 patients (increased in SEGA volume with or without ventricular enlargement). Surgical treatment consisted in a frontal trans-ventricular microsurgical approach in 17 patients and an endoscopic approach in 1. External ventricular drainage was placed in all the patients but 1. Ventriculoperitoneal shunting (VPS) became necessary in 6 patients, all of them presenting with a preoperative active hydrocephalus. Morbidity appeared very low with meningitis occurring in 1 patient. Resection was complete in 15 children with no recurrence during a mean follow-up of 5.25 years and incomplete in 3 requiring a second surgery.
CONCLUSION: Surgery of SEGA represents a very effective treatment with low morbidity and no mortality in the present series. In patients operated before the onset of clinical signs of hydrocephalus, internal VPS could be avoided whereas in others, an additional shunt surgery became necessary. This gives arguments in favor of a regular MRI surveillance in tuberous sclerosis complex patients with SEGA in order to best propose resective surgery once a growth of tumor and/or ventricular size have been confirmed but before raised intracranial pressure occurs.

Entities:  

Keywords:  Brain tumor; Hydrocephalus; Pediatric; Ventriculoperitoneal shunt

Mesh:

Year:  2018        PMID: 29766265     DOI: 10.1007/s00381-018-3826-6

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.475


  37 in total

Review 1.  Neurological manifestations of tuberous sclerosis complex.

Authors:  P Curatolo
Journal:  Childs Nerv Syst       Date:  1996-09       Impact factor: 1.475

2.  Prevalence of tuberous sclerosis estimated by capture-recapture analysis.

Authors:  F J O'Callaghan; A W Shiell; J P Osborne; C N Martyn
Journal:  Lancet       Date:  1998-05-16       Impact factor: 79.321

3.  Genetic aspects of tuberous sclerosis in the west of Scotland.

Authors:  J R Sampson; S J Scahill; J B Stephenson; L Mann; J M Connor
Journal:  J Med Genet       Date:  1989-01       Impact factor: 6.318

4.  Imaging characteristics and growth of subependymal giant cell astrocytomas.

Authors:  Michelle J Clarke; Andrew B Foy; Nicholas Wetjen; Corey Raffel
Journal:  Neurosurg Focus       Date:  2006-01-15       Impact factor: 4.047

5.  The clinicopathologic spectrum of focal cortical dysplasias: a consensus classification proposed by an ad hoc Task Force of the ILAE Diagnostic Methods Commission.

Authors:  Ingmar Blümcke; Maria Thom; Eleonora Aronica; Dawna D Armstrong; Harry V Vinters; Andre Palmini; Thomas S Jacques; Giuliano Avanzini; A James Barkovich; Giorgio Battaglia; Albert Becker; Carlos Cepeda; Fernando Cendes; Nadia Colombo; Peter Crino; J Helen Cross; Olivier Delalande; François Dubeau; John Duncan; Renzo Guerrini; Philippe Kahane; Gary Mathern; Imad Najm; Ciğdem Ozkara; Charles Raybaud; Alfonso Represa; Steven N Roper; Noriko Salamon; Andreas Schulze-Bonhage; Laura Tassi; Annamaria Vezzani; Roberto Spreafico
Journal:  Epilepsia       Date:  2010-11-10       Impact factor: 5.864

6.  On the treatment of subependymal giant cell astrocytomas and associated hydrocephalus in tuberous sclerosis.

Authors:  C Di Rocco; A Iannelli; E Marchese
Journal:  Pediatr Neurosurg       Date:  1995       Impact factor: 1.162

Review 7.  Tuberous sclerosis complex consensus conference: revised clinical diagnostic criteria.

Authors:  E S Roach; M R Gomez; H Northrup
Journal:  J Child Neurol       Date:  1998-12       Impact factor: 1.987

8.  Subependymal giant cell astrocytoma: a report of five cases.

Authors:  Raj Kumar; Vinita Singh
Journal:  Neurosurg Rev       Date:  2004-08-12       Impact factor: 3.042

9.  Identification and characterization of the tuberous sclerosis gene on chromosome 16.

Authors: 
Journal:  Cell       Date:  1993-12-31       Impact factor: 41.582

10.  Subependymal giant cell astrocytoma: diagnosis, screening, and treatment. Recommendations from the International Tuberous Sclerosis Complex Consensus Conference 2012.

Authors:  Jonathan Roth; E Steve Roach; Ute Bartels; Sergiusz Jóźwiak; Mary Kay Koenig; Howard L Weiner; David N Franz; Henry Z Wang
Journal:  Pediatr Neurol       Date:  2013-10-15       Impact factor: 3.372

View more
  5 in total

Review 1.  Syndromic Hydrocephalus.

Authors:  Kaamya Varagur; Sai Anusha Sanka; Jennifer M Strahle
Journal:  Neurosurg Clin N Am       Date:  2022-01       Impact factor: 2.509

2.  Growth Curves of Subependymal Giant Cell Tumors in Tuberous Sclerosis Complex.

Authors:  J R Barnett; J H Freedman; H Zheng; E A Thiele; P Caruso
Journal:  AJNR Am J Neuroradiol       Date:  2021-10       Impact factor: 4.966

3.  Current trends in the management of subependymal giant cell astrocytomas in tuberous sclerosis.

Authors:  Paolo Frassanito; Carolina Noya; Gianpiero Tamburrini
Journal:  Childs Nerv Syst       Date:  2020-09-25       Impact factor: 1.475

4.  Identification of TSC1 or TSC2 mutation limited to the tumor in three cases of solitary subependymal giant cell astrocytoma using next-generation sequencing technology.

Authors:  Martine Fohlen; Ines Harzallah; Marc Polivka; Fabienne Giuliano; Linda Pons; Nathalie Streichenberger; Georg Dorfmüller; Renaud Touraine
Journal:  Childs Nerv Syst       Date:  2020-02-26       Impact factor: 1.475

5.  Experience using mTOR inhibitors for subependymal giant cell astrocytoma in tuberous sclerosis complex at a single facility.

Authors:  Kyoichi Tomoto; Ayataka Fujimoto; Chikanori Inenaga; Tohru Okanishi; Shin Imai; Masaaki Ogai; Akiko Fukunaga; Hidenori Nakamura; Keishiro Sato; Akira Obana; Takayuki Masui; Yoshifumi Arai; Hideo Enoki
Journal:  BMC Neurol       Date:  2021-03-31       Impact factor: 2.474

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.